Healthcare deal value in the second quarter totaled $138.7 billion, a slight 7% decrease from the first quarter’s $149.0 billion. Both quarters in 2019 featured a single, mega-billion-dollar deal—the $74 billion Bristol-Myers Squibb/Celgene deal in Q1 and the $87 billion AbbVie/Allergan hook-up in Q2—while the second quarter of 2018 included Takeda’s $81.5 billion deal for […]
With 431 deals announced in the second quarter, acquisition activity was 9% higher than the 394 transactions announced in the previous quarter. Year over year, however, deal volume was 11% lower than the same quarter in 2018, which had 484 deals. The first quarter of 2019 was the slowest of the previous four quarters, at […]
Second quarter deal volume was robust, based on preliminary results. Some 424 deals are on the books for the quarter, representing an 8% increase over the first quarter (394 deals). It’s still a hard comparison with Q2:18 numbers, which had 484 announcements, 12% higher than this year’s period. Spending remained high in the second quarter, […]
With 374 deals announced in the first quarter, acquisition activity was 25% lower than the 498 transactions announced in the previous quarter. Deal volume was also lower than the same quarter in 2018, down 16% compared with the 447 deals reported then. Deal volume in all four quarters of 2018 consistently closed above 440 deals, […]
Spending in the first quarter roared to nearly $150 billion, up 240% compared with the fourth quarter ($43.9 billion) and up 32% compared with the first quarter in 2018 ($113.4 billion). This quarter’s total would be halved if it weren’t for a single deal with a $74 billion price tag, Bristol-Myers Squibb’s (NYSE: BMY) acquisition […]
Talk of slowing global economic growth has swirled since late last year, following tariffs, trade wars, Brexit and you-name-it. The healthcare M&A market appeared to reflect the fears, as deal volume in the first quarter of 2019 slid 27% compared with the fourth quarter of 2018, and was down 19% compared with the same quarter […]
Spending in the first quarter, totaling $149 billion, beat both the previous quarter (up 239%) and the year-ago time period (up 31%). Three deals had a combined total of $113 billion, accounting for 76% of that spending. Without those three, the first quarter would have ended with approximately $36 billion, which would be 18% lower […]
Deal volume has climbed higher every year since 2012. Spending on those deals hasn’t been as predictable, which is why we watch deal volume more closely. But dollar signs attract attention, so here is where the preliminary results point. Combined spending in 2018 now stands at $330.3 billion and may rise slightly higher as we […]
It’s broken record time. Every January for the past six years, we’ve led with a story that says the previous year broke the record for healthcare deal volume. Why break a streak? More than 1,850 healthcare deals were announced in 2018, 14% more than in 2017 and by far the most we’ve ever reported. It […]
A total of $30.4 billion was spent to fund the 435 transactions reported in Q3:18, based on disclosed prices. The Hospital sector dominated the dollar side of deal making for the first time since 2013, accounting for 27% ($8.2 billion) of spending. A single deal accounted for 68% of the Hospital sector’s total, as RCCH […]
